INTRODUCTION
============

Diabetes mellitus is a leading cause of mortality, with an estimated 1.3 million diabetes-related deaths worldwide in 2010, which is twice as many as occurred in 1990 \[[@B1]\]. Diabetes and diabetes-related chronic complications, such as retinopathy, neuropathy, nephropathy, cardiovascular, and cerebrovascular diseases, peripheral artery occlusive diseases, and amputations, also significantly increase medical costs \[[@B2][@B3][@B4]\]. While the prevalence of diabetes is increasing in Korea, proper glycemic control has not been achieved in Korean type 2 diabetes mellitus (T2DM) patients \[[@B5][@B6]\]. The risk of diabetic complications is strongly associated with hyperglycemia, whereas proper glycemic control is likely to reduce complications \[[@B2][@B7]\].

Recently, research based on -omics data has been on the rise following the rapid development of large-scale genome analysis techniques. Such studies may be particularly valuable in T2DM, which is a complex and multifactorial disease with variable clinical features and courses \[[@B8]\]. Success in metabolomics studies relies on proper sample preparation, innovative instrumentation, and bioinformatics tools \[[@B9]\]. The unmet need for a long-term prospective study based on -omics data might be partly due to the difficulty of collecting standardized clinical and biological data \[[@B10]\].

In this context, the establishment of a structurally designed large-scale registry with standardized data collection methods is needed to draw clinically significant conclusions. This study is part of a national project to provide standardized clinical data and biospecimens for future long-term prospective studies. It is a fundamental study aimed at identifying the properties of diabetic retinopathy (DR) and macular edema (ME) in Korean T2DM patients. Our main goal was to compare the characteristics of long-standing T2DM patients with their DR and/or ME status. DR and ME were used as criteria because they are the most specific complications of T2DM \[[@B11]\].

METHODS
=======

Subjects and study design
-------------------------

This cross-sectional study was carried out as part of a prospective study at Kyung Hee University Hospital in Korea. From September 2014 to July 2015, T2DM patients with disease duration of longer than 15 years were recruited. Clinical data, along with blood and urine samples, were collected from each participant after obtaining informed consent. The statuses of DR and ME were assessed in each participant through ophthalmological exams.

Common data elements and standard operating procedure
-----------------------------------------------------

To secure standardized clinical and biochemical data and to establish a practical action plan, common data elements (CDEs) and standard operating procedures (SOPs) were established. CDEs were initially selected from the case report form (CRF) of a previous Korea National Diabetes Program (KNDP) cohort study \[[@B2]\]. Then the initial draft of the CRF was established by referring to the critical items recommended by the Korean Diabetes Association (KDA) and the American Diabetes Association clinical guidelines \[[@B12][@B13]\]. The SOP was established referring to methods from Korean National Biobank guidelines \[[@B14]\].

The final forms of the CRF and SOP were announced and confirmed at the opening symposium of the KDA clinical standardization group in January 2015. It was then approved by the board of directors of the KDA in July 2015 Participant clinical data were managed electronically through the iCReaT (Internet based Clinical Research and Trial management) System (Korea Centers for Disease Control and Prevention, Cheongju, Korea), which was developed by the Korea National Research Institute of Health for multicenter registration and long-term follow-up.

Outcome definition
------------------

The DR status of each participant was assessed through color fundus photographs (FF 450 Plus; Carl Zeiss Meditec, Jena, Germany). According to Early Treatment Diabetic Retinopathy Study (ETDRS) criteria, DR was graded into three categories: no DR, non-proliferative diabetic retinopathy (NPDR), or proliferative diabetic retinopathy (PDR) \[[@B15][@B16]\]. If the eyes of a single patient were rated at different stages, the grade of the worse eye was used. The presence of DME was confirmed using thickness measurements as assessed by Cirrus High-Definition Optical Coherence Tomography (HD-OCT; Carl Zeiss Meditec, Dublin, CA, USA). Two or more ophthalmologists classified the DR and ME statuses based on the exam results. In cases of discordance between the evaluators, they reviewed the images again and agreed on the final interpretation.

Trained interviewers assessed the presence of underlying comorbidities by surveying the participants and checking the medical records for the use of relevant medications. The status of physical activities and other socioeconomic statuses were also assessed through interviews. Obesity was defined as a body mass index at or above 25 kg/m^2^. Dyslipidemia was defined as raised triglyceride (≥150 mg/dL) and/or low high density lipoprotein cholesterol (\<40 mg/dL in men and \<50 mg/dL in women) or on a specific treatment, according to the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults \[[@B17]\].

Ethics statement
----------------

This study was approved by the Institutional Review Board of Kyung Hee University Hospital (IRB No. KMC IRB 1428-04). Written informed consent was obtained from all participants. Data from this study were registered at the Clinical Research Information Service (CRIS, No. KCT0001269). CRIS is a Korean National Service connected to the International Clinical Trials Registry Platform of the World Health Organization.

Statistical analyses
--------------------

Means, proportions, and distributions of characteristics were compared between patients with or without DR and ME. Chi-square tests were used to measure the significance of associations for categorical variables, and Student *t*-tests for continuous variables. Multiple logistic regression analysis was performed to assess the independent contribution of variables to DR and/or ME. Variables that were significant in univariate analyses were included as covariates in the model. Statistical analyses were conducted independently by a specialized statistician at the Statistics Support Department of Kyung Hee University Medical Center Medical Science Research Institute. SAS software version 9.3 (SAS Institute Inc., Cary, NC, USA) was used to perform all statistical tests.

RESULTS
=======

Study progression
-----------------

Among 220 patients recruited, clinical data and samples were collected from 198 patients who consented to the study. A total of 183 ophthalmologic exams were completed ([Fig. 1](#F1){ref-type="fig"}). The mean age of the participants was 66.8 years, the median duration of DM was 22.6 years, and 49.7% of the participants were male.

Comparison of characteristics with DR status
--------------------------------------------

[Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} show selected characteristics compared to the grade of DR. Among a total of 183 participants who underwent ophthalmological assessment, 124 (67.76%) were diagnosed with DR. A total of 72 patients (39.3%) had NPDR and 52 (28.4%) had PDR. Statistically significant differences were found for several factors.

More severe DR was associated with a younger age (70±11 years old without DR, 66±12.25 years old with NPDR, and 62±17 years old with PDR, *P*=0.001) and longer duration of DM (20±6 years without DR, 22±7 years with NPDR, and 23.5±9 years with PDR, *P*=0.022). Urine microalbumin levels (7.9±14.8 µg/mg Cr without DR, 12.55±33.55 µg/mg Cr with NPDR, and 48.2±302.6 µg/mg Cr with PDR, *P*\<0.001) and serum creatinine levels (0.7±0.4 mg/dL without DR, 0.8±0.4 mg/dL with NPDR, and 0.85±0.5 mg/dL with PDR, *P*=0.017) were higher and creatinine clearance was lower (101.4±42.75 mL/min without DR, 90±40.62 mL/min with NPDR, and 83.6±49.12 mL/min with PDR, *P*=0.044) in patients with more severe DR. In addition, patients with more severe DR had a lower γ-glutamyltransferase level (24±21 U/L without DR, 27±18.25 U/L with NPDR, and 18±13 U/L with PDR, *P*=0.001). Groups with more severe DR had a higher proportion of patients with a family history of cardiovascular disease (1.8% without DR, 2.8% with NPDR, and 12% with PDR, *P*=0.050), but less of a family history of cancer (36.2% without DR, 22.5% with NPDR, and 15.7% with PDR, *P*=0.045) ([Table 1](#T1){ref-type="table"}). A greater proportion of patients were using rapid-acting insulin (1.7% without DR, 18.1% with NPDR, and 25% with PDR, *P*\<0.001), long-acting insulin (20.3% without DR, 38.9% with NPDR, and 50% with PDR, *P*=0.004), and β-blockers (3.4% without DR, 13.9% with NPDR, and 19.2% with PDR, *P*=0.024) in groups with more severe DR. A larger proportion of patients in the groups with more severe DR had less physical activity (*P*=0.041) and fewer incidences of exercise per week (*P*=0.021) ([Table 2](#T2){ref-type="table"}).

Among microvascular complications, patients with more severe DR had a greater prevalence of microalbuminuria (30.5% without DR, 36.1% with NPDR, and 67.3% with PDR, *P*\<0.001), overt proteinuria (10.2% without DR, 18.1% with NPDR, and 36.5% with PDR, *P*=0.003), and autonomic neuropathy (24.1% without DR, 29.9% with NPDR, and 46.8% with PDR, *P*=0.043). In addition, the prevalence of dyslipidemia was significantly different among the three groups (*P*=0.018) ([Table 2](#T2){ref-type="table"}).

Comparison of characteristics with ME status
--------------------------------------------

[Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} show selected characteristics comparing values in the presence or absence of ME. Among a total of 182 participants assessed with OCT, ME was present in 46 (25.27%). As with DR, statistically significant differences were found for several factors ([Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Patients with ME were younger (66.5±12 years old vs. 63.5±15.5 years old, *P*=0.049), had a longer duration of DM (21±7.5 years vs. 23.5±7 years, *P*=0.037), and a larger proportion of patients were female (45.6% vs. 65.2%, *P*=0.027). Glycosylated hemoglobin (7.75%±1.82% vs. 8.25%±2.35%, *P*=0.029) and urine microalbumin (11.45±27.55 µg/mg Cr vs. 32.45±210.03 µg/mg Cr, *P*=0.001) levels were higher, along with a higher prevalence of overt proteinuria (16.9% vs. 32.6%, *P*=0.035) in the ME group ([Table 3](#T3){ref-type="table"}).

A greater proportion of patients underwent inpatient treatment (22.8% vs. 39.1%, *P*=0.036) and surgery (10.3% vs. 30.4%, *P*=0.002) within the past year. They had a higher prevalence of a family history of cardiovascular disease (1.5% vs. 15.9%, *P*=0.001). A significantly higher proportion of ME patients were using rapid-acting insulin (11.0% vs. 26.1%, *P*=0.017), but there was no significant difference in the use of long-acting (*P*=0.479) or premixed insulin (*P*=0.837) ([Table 4](#T4){ref-type="table"}).

Multivariate analyses for DR
----------------------------

Multivariate logistic regression analyses were conducted according to the characteristics of the variables shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Several factors were found to be significantly associated with DR ([Fig. 2](#F2){ref-type="fig"}). Younger age (odds ratio \[OR\], 0.874; 95% confidence interval \[CI\], 0.820 to 0.930; *P*\<0.001) and lower creatinine clearance (OR, 0.972; 95% CI, 0.950 to 0.995; *P*=0.015) were associated with PDR. NPDR was associated with higher fasting plasma glucose levels (OR, 1.011; 95% CI, 1.004 to 1.019; *P*=0.004), lower urine microalbumin levels (OR, 0.996; 95% CI, 0.992 to 1.000; *P*=0.039), and less use of sulfonylurea (OR, 0.417; 95% CI, 0.175 to 0.996; *P*=0.049). In addition, longer duration of DM (OR, 1.071; 95% CI, 1.001 to 1.147; *P*=0.048 for NPDR) (OR, 1.142; 95% CI, 1.051 to 1.242; *P*=0.002 for PDR) and the use of long-acting insulin (OR, 4.559; 95% CI, 1.672 to 12.427; *P*=0.003 for NPDR) (OR, 4.783; 95% CI, 1.581 to 14.474; *P*=0.006 for PDR) were identified as independent risk factors for both NPDR and PDR, whereas a family history of cancer was identified as a negative risk factor (OR, 0.310; 95% CI, 0.119 to 0.809; *P*=0.017 for NPDR) (OR, 0.206; 95% CI, 0.063 to 0.673; *P*=0.009 for PDR).

Multivariate analyses for ME
----------------------------

Several factors were found to be significantly associated with ME in multivariate logistic regression analysis ([Fig. 3](#F3){ref-type="fig"}). Lower body weight (OR, 0.923; 95% CI, 0.856 to 0.995; *P*=0.036), lower systolic blood pressure (OR, 0.970; 95% CI, 0.942 to 1.000; *P*=0.047), and lower levels of alanine transaminase (OR, 0.863; 95% CI, 0.793 to 0.940; *P*\<0.001) were associated with ME. Higher glycosylated hemoglobin levels (OR, 1.380, 95% CI, 1.032 to 1.845; *P*=0.030), peripheral neuropathy (OR, 2.523; 95% CI, 1.026 to 6.202; *P*=0.044), family history of obesity (OR, 3.017; 95% CI, 1.075 to 8.465; *P*=0.036), history of surgery within the past year (OR, 3.618; 95% CI, 1.266 to 10.339; *P*=0.016), and the use of rapid-acting insulin (OR, 5.211; 95% CI, 1.445 to 18.794; *P*=0.012) were confirmed as independent risk factors for ME.

DISCUSSION
==========

A registry-based study for standardized clinical research
---------------------------------------------------------

The authors have been running the KNDP since May 2006 \[[@B2]\]. The KNDP is a large-scale multicenter prospective cohort study that was established to observe the long-term clinical course of Korean T2DM patients \[[@B18]\]. It consists of 4,600 T2DM patients collected from 13 Korean university hospitals. A well-structured systemically designed registry was established based on the knowledge and skills obtained through experiences with the KNDP cohort. Initially, it was designed as a case-control study on DR and a control group, but it was changed to a cohort-based study, which provides a higher level of evidence in clinical medicine. The goal of further studies is to perform long-term observations with a larger sample size based on the cohort of this study.

Summary of findings
-------------------

In this study, we confirmed various clinical features associated with the occurrence of DR and ME. DR was associated with higher levels of fasting plasma glucose, longer duration of DM, and greater use of long-acting insulin, but a lower prevalence of a family history of cancer. ME was associated with higher levels of glycosylated hemoglobin, a greater prevalence of surgery within the past year, and greater use of rapid-acting insulin.

Comparison with previous studies (1): diabetic retinopathy
----------------------------------------------------------

The duration of DM, hyperglycemia, and hypertension are known to be major risk factors for DR \[[@B19][@B20]\]. Diabetic nephropathy is also strongly associated with DR \[[@B21]\]. These findings are also valid in the Korean population \[[@B22][@B23]\]. Our results were consistent with previous findings in many ways, but some were inconsistent. For instance, we could not find a significant association of blood pressure with the presence or grade of DR. However, the use of β-blockers was significantly higher in the NPDR and PDR groups than in the group without DR.

We obtained significant results for several factors that showed unclear significance or inconsistent results in previous studies. A younger age was associated with DR in our study. This might imply the association of DR with the diagnosis of T2DM at a younger age because our study only included T2DM patients with disease duration of longer than 15 years. The use of rapid- and long-acting insulin was associated with DR, which showed inconsistent results as a risk factor in previous studies \[[@B21]\].

Comparison with previous studies (2): macular edema
---------------------------------------------------

In addition to the major risk factors identified for DR, dyslipidemia is also known to be a strong risk factor for ME \[[@B22]\]. As with DR, some of the findings in our study were inconsistent with previous findings. Systolic blood pressure, underlying hypertension, and the use of any antihypertensive medication did not differ between the non-ME group and the ME group.

As with DR, a younger age and the use of long-acting insulin were associated with ME. The proportion of females was higher and body weight was lower in patients with ME. In addition, levels of alanine transaminase and γ-glutamyltransferase were lower in the ME group. A history of hospitalization and surgery within the past year was associated with ME. The mechanisms underlying most of these findings are not yet fully understood.

Clinical implications and future research plans
-----------------------------------------------

Various environmental factors are considered to be significantly associated with the development of T2DM and related chronic complications. Genetic factors are also considered important in disease progression and aggravation \[[@B21]\]. Although much effort has been expended on elucidating significant genetic factors and their influences in the clinical course of T2DM and its complications, the results thus far have not been fully satisfying. One possible reason for this is the difficulty of managing various types of clinical information and biospecimens by a consensus-based methodology, despite recent advances in genotyping technology. Therefore, we should pay more attention to obtaining detailed and accurate information in clinical phenotyping for breakthroughs in relevant research.

To overcome the above problem, we established the research group on clinical data standardization for diabetes research at the KDA and prepared the draft of standardized data elements and standard procedures for multicenter patient registration and biospecimen collection. With this system, we organized a multicenter, prospective cohort for DR, initiated a genome-wide association study to verify performance, and encouraged participation by other investigators. Recently, this system was approved by the members of the KDA\'s board of directors.

In addition, we only included patients with long-standing T2DM in our study, which is distinct from previous studies. This unique study design was based on the hypothesis that there are several genetic and environmental factors that are protective against the development of diabetic complications. In addition, outcome definitions were clarified via ophthalmologic assessment by ophthalmology specialists, enhancing our confidence in the results.

Some of the results were inconsistent with the conventional risk factors established in previous studies. This might have been due to the limitations of our study. First, it was a single-center study with a small sample size. Second, causal relationships could not be identified since it was a cross-sectional study performed on baseline data. Third, the main reason for withdrawal was difficulty in performing complete ophthalmologic exams. This might have led to selection bias by excluding patients with poor performance status.

We are planning a 10-year follow-up of the data collected in this study, and additional recruitment is in progress. The limitations of the current study can be overcome by integrating data with other centers. This can be easily done through the electronic CRFs, CDEs, and SOPs established in this study. Future longitudinal studies will focus on identifying biomarkers associated with diabetic complications and assessing responses to medical treatment.
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###### Comparison of characteristics with DR status
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  Variable                         Without DR    NPDR           PDR            *P*value
  -------------------------------- ------------- -------------- -------------- ----------
  Number                           59 (32.2)     72 (39.3)      52 (28.4)      
  Sex                                                                          0.301
   Male                            27 (45.8)     41 (56.9)      23 (44.2)      
   Female                          32 (54.2)     31 (43.1)      29 (55.8)      
  Age, yr                          70±11         66±12.25       62±17          0.001
  Duration of DM, yr               20±6          22±7           23.5±9         0.022
  Body mass index, kg/m^2^         24.66±3.12    24.7±3.26      24.21±3.45     0.694
  Body weight, kg                  63.4±12.45    64.36±10.67    62.52±10.28    0.606
  Systolic blood pressure, mm Hg   127.9±15.98   127.99±14.26   124.46±13.92   0.332
  Glycosylated hemoglobin, %       7.7±2         8±2.1          8.05±2.1       0.097
  Fasting plasma glucose, mg/dL    134±59.5      158±69.5       151.5±80.25    0.060
  LDL-C, mg/dL                     102±37        95±37.5        85±42.5        0.139
  Urine microalbumin, µg/mg Cr     7.9±14.8      12.55±33.55    48.2±302.6     \<0.001
  Serum creatinine, mg/dL          0.7±0.4       0.8±0.4        0.85±0.5       0.017
  Creatinine clearance, mL/min     101.4±42.75   90±40.62       83.6±49.12     0.044
  Alanine transaminase, U/L        18±10.5       18±10.25       16±8           0.063
  γ-Glutamyltransferase, U/L       24±21         27±18.25       18±13          0.001
  Physical activity and habits                                                 0.263
   Alcohol use                                                                 
    Never                          34 (57.6)     36 (50)        35 (67.3)      
    Former                         5 (8.5)       12 (16.7)      6 (11.5)       
    Current                        20 (33.9)     24 (33.3)      11 (21.2)      
   Smoking status                                                              0.089
    Never                          35 (59.3)     40 (55.6)      33 (63.5)      
    Former                         19 (32.2)     16 (22.2)      8 (15.4)       
    Current                        5 (8.5)       16 (22.2)      11 (21.2)      
   Daily activity within a year                                                0.041
    Nearly bed-ridden              0             3 (4.2)        6 (11.5)       
    Light                          28 (47.5)     39 (54.2)      29 (55.8)      
    Moderate                       29 (49.2)     24 (33.3)      15 (28.8)      
    Heavy                          2 (3.4)       6 (8.3)        2 (3.8)        
   Regular exercise, times/week    3±6.5         3±5            0±5            0.021
  Family history DM                35 (60.3)     49 (72.1)      41 (78.8)      0.107
   Hypertension                    27 (50.9)     24 (43.6)      25 (53.2)      0.654
   Dyslipidemia                    4 (9.8)       3 (6.5)        3 (8.8)        0.844
   Obesity                         12 (20.3)     19 (27.1)      13 (25)        0.689
   Cardiovascular disease          1 (1.8)       2 (2.8)        6 (12)         0.050
   Stroke                          13 (23.2)     7 (9.7)        6 (12)         0.096
   Cancer                          21 (36.2)     16 (22.5)      8 (15.7)       0.045

Values are presented as number (%) or mean±standard deviation. *P* value for the chi-square test comparing the groups with and without DR. Statistical comparisons were performed using the chi-square test (nominal data) or the Mann-Whitney *U* test (continuous data).

DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; DM, diabetes mellitus; LDL-C, low density lipoprotein cholesterol.

###### Comparison of the underlying comorbidities and the use of medications with a grade of DR
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  Variable                            Without DR   NPDR        PDR         *P* value
  ----------------------------------- ------------ ----------- ----------- -----------
  Hypertension                        44 (74.6)    63 (87.5)   43 (82.7)   0.188
  Dyslipidemia                        42 (71.2)    56 (77.8)   28 (53.8)   0.018
  Myocardial infarction               0            1 (1.4)     0           1.000
  Angina                              5 (8.5)      10 (13.9)   6 (11.5)    0.672
  Heart failure                       0            2 (2.8)     2 (3.8)     0.386
  Stroke (hemorrhage)                 1 (1.7)      1 (1.4)     1 (1.9)     1.000
  Stroke (infarction)                 9 (15.3)     9 (12.5)    7 (13.5)    0.962
  Peripheral arterial disease         3 (5.1)      7 (9.7)     6 (11.5)    0.482
  Hospitalization within past year    11 (18.6)    18 (25)     20 (38.5)   0.057
  Operation within past year          7 (11.9)     10 (13.9)   11 (21.2)   0.366
  Microvascular complication                                               
   Microalbuminuria                   18 (30.5)    26 (36.1)   35 (67.3)   \<0.001
   Overt proteinuria                  6 (10.2)     13 (18.1)   19 (36.5)   0.003
   Chronic kidney disease             11 (18.6)    9 (12.5)    15 (28.8)   0.076
   Peripheral neuropathy              27 (45.8)    36 (50)     25 (49.0)   0.896
   Autonomic neuropathy               14 (24.1)    20 (29.9)   22 (46.8)   0.043
  Medications                                                              
   Metformin                          39 (66.1)    50 (69.4)   36 (69.2)   0.920
   Sulfonylurea                       41 (69.5)    40 (55.6)   26 (50)     0.089
   Dipeptidyl peptidase-4 inhibitor   24 (40.7)    19 (26.4)   12 (23.1)   0.096
   Meglitinide                        1 (1.7)      3 (4.2)     4 (7.7)     0.305
   Thiazolidinedione                  2 (3.4)      2 (2.8)     3 (5.8)     0.715
   α-Glucosidase inhibitor            0            1 (1.4)     1 (1.9)     0.745
   SGLT-2 inhibitor                   0            0           0           \-
   GLP-1 agonist                      0            0           0           \-
   Rapid-acting insulin               1 (1.7)      13 (18.1)   13 (25)     \<0.001
   Long-acting insulin                12 (20.3)    28 (38.9)   26 (50)     0.004
   Premixed insulin                   12 (20.3)    14 (19.4)   12 (23.1)   0.872
   Angiotensin II receptor blocker    30 (50.8)    37 (51.4)   23 (44.2)   0.709
   ACEi                               3 (5.1)      7 (9.7)     7 (13.5)    0.325
   Calcium channel blockers           24 (40.7)    22 (30.6)   19 (36.5)   0.471
   Diuretics                          8 (13.6)     8 (11.1)    6 (11.5)    0.920
   β-Blockers                         2 (3.4)      10 (13.9)   10 (19.2)   0.024
   Statin                             28 (47.5)    46 (63.9)   27 (51.9)   0.147
   Aspirin                            13 (22.0)    1 (1.4)     11 (21.2)   0.947
   Clopidogrel                        10 (16.9)    14 (19.4)   4 (7.7)     0.167
   Cilostazol                         28 (47.5)    28 (38.9)   13 (25)     0.051

Values are presented as number (%). *P* value for the chi-square test comparing the groups with and without DR. Statistical comparisons were performed using the chi-square test (nominal data) or the Mann-Whitney *U* test (continuous data).

DR, diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; SGLT-2, sodium/glucose co-transporter 2; GLP-1, glucagon-like peptide-1; ACEi, angiotensin-converting enzyme inhibitor.

###### Comparison of characteristics with ME status
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  Variable                         Without ME     With ME        *P*value
  -------------------------------- -------------- -------------- ----------
  Number                           136            46             
  Sex                                                            0.027
   Male                            74 (54.4)      16 (34.8)      
   Female                          62 (45.6)      30 (65.2)      
  Age, yr                          66.5±12        63.5±15.5      0.049
  Duration of DM, yr               21±7.5         23.5±7         0.037
  Body mass index, kg/m^2^         24.6±3.95      23.95±4.83     0.412
  Body weight, kg                  64.76±10.27    60.6±8.93      0.015
  Systolic blood pressure, mm Hg   127.96±14.75   124.63±14.09   0.182
  Glycosylated hemoglobin, %       7.75±1.82      8.25±2.35      0.029
  Fasting plasma glucose, mg/dL    145.5±68.75    166±73.5       0.590
  LDL-C, mg/dL                     97±38.5        96.5±40.25     0.561
  Urine microalbumin, µg/mg Cr     11.45±27.55    32.45±210.03   0.001
  Serum creatinine, mg/dL          0.8±0.4        0.8±0.38       0.477
  Creatinine clearance, mL/min     93.91±38.09    84±34.9        0.121
  Alanine transaminase, U/L        18±12          14±5           \<0.001
  γ-Glutamyltransferase, U/L       26±19          19±12          0.001
  Physical activity and habits                                   
   Alcohol use                                                   0.066
    Never                          72 (52.9)      33 (71.7)      
    Former                         18 (13.2)      5 (10.9)       
    Current                        46 (33.8)      8 (17.4)       
   Smoking status                                                0.538
    Never                          78 (57.4)      30 (65.2)      
    Former                         34 (25)        8 (17.4)       
    Current                        24 (17.6)      8 (17.4)       
   Daily activity within a year                                  0.056
    Nearly bed-ridden              6 (4.4)        3 (6.5)        
    Light                          65 (47.8)      30 (65.2)      
    Moderate                       55 (40.4)      13 (28.3)      
    Heavy                          10 (7.4)       0              
   Regular exercise, times/week    3±5.5          1.5±5          0.171
  Family history                                                 
   DM                              90 (68)        34 (75.6)      0.451
   Hypertension                    51 (44.7)      24 (60)        0.103
   Dyslipidemia                    8 (8.4)        2 (7.7)        1.000
   Obesity                         28 (20.9)      16 (34.8)      0.074
   Cardiovascular disease          2 (1.5)        7 (15.9)       0.001
   Stroke                          21 (15.8)      4 (9.1)        0.327
   Cancer                          34 (25.2)      11 (25)        1.000

Values are presented as number (%) or mean±standard deviation. *P* value for the chi-square test comparing the groups with and without ME. Statistical comparisons were performed using the chi-square test (nominal data) or the Mann-Whitney *U* test (continuous data).

ME, macular edema; DM, diabetes mellitus; LDL-C, low density lipoprotein cholesterol.

###### Comparison of the underlying comorbidities and medication use with the presence of ME

![](dmj-41-393-i004)

  Variable                            Without ME   With ME     *P* value
  ----------------------------------- ------------ ----------- -----------
  Hypertension                        111 (81.6)   38 (82.6)   1.000
  Dyslipidemia                        96 (70.6)    29 (63.0)   0.362
  Myocardial infarction               1 (0.7)      0           1.000
  Angina                              13 (9.6)     7 (15.2)    0.286
  Heart failure                       2 (1.5)      2 (4.3)     0.265
  Stroke (hemorrhage)                 3 (2.2)      0           0.573
  Stroke (infarction)                 20 (14.7)    5 (10.9)    0.573
  Peripheral arterial disease         10 (7.4)     5 (10.9)    0.535
  Hospitalization within past year    31 (22.8)    18 (39.1)   0.036
  Operation within past year          14 (10.3)    14 (30.4)   0.002
  Microvascular complication                                   
   Retinopathy                        69 (50.7)    42 (91.3)   \<0.001
   Microalbuminuria                   53 (39.0)    26 (56.5)   0.041
   Overt proteinuria                  23 (16.9)    15 (32.6)   0.035
   Chronic kidney disease             25 (18.4)    10 (21.7)   0.666
   Peripheral neuropathy              61 (44.9)    27 (60)     0.087
   Autonomic neuropathy               38 (29.5)    18 (42.9)   0.131
  Medications                                                  
   Metformin                          94 (69.1)    30 (65.2)   0.715
   Sulfonylurea                       84 (61.8)    22 (47.8)   0.120
   Dipeptidyl peptidase-4 inhibitor   43 (31.6)    11 (23.9)   0.356
   Meglitinide                        4 (2.9)      4 (8.7)     0.113
   Thiazolidinedione                  4 (2.9)      3 (6.5)     0.371
   α-Glucosidase inhibitor            2 (1.5)      0           1.000
   SGLT-2 inhibitor                   0            0           \-
   GLP-1 agonist                      0            0           \-
   Rapid-acting insulin               15 (11.0)    12 (26.1)   0.017
   Long-acting insulin                47 (34.6)    19 (41.3)   0.479
   Premixed insulin                   28 (20.6)    10 (21.7)   0.837
   Angiotensin II receptor blocker    70 (51.5)    19 (41.3)   0.306
   ACEi                               10 (7.4)     7 (15.2)    0.142
   Calcium channel blockers           49 (36.0)    16 (34.8)   1.000
   Diuretics                          17 (12.5)    5 (10.9)    1.000
   β-Blockers                         17 (12.5)    5 (10.9)    1.000
   Statin                             72 (52.9)    28 (60.9)   0.394
   Aspirin                            31 (22.8)    7 (15.2)    0.304
   Clopidogrel                        22 (16.2)    5 (10.9)    0.477
   Cilostazol                         55 (40.4)    14 (30.4)   0.292

Values are presented as number (%). *P* value for the chi-square test comparing the groups with and without ME. Statistical comparisons were performed using the chi-square test (nominal data) or the Mann-Whitney *U* test (continuous data).

ME, macular edema; SGLT-2, sodium/glucose co-transporter 2; GLP-1, glucagon-like peptide-1; ACEi, angiotensin-converting enzyme inhibitor.

[^1]: ^\*^Sejeong Park and Sang Youl Rhee contributed equally to this study as first authors.
